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Abstract
Nkx2.5 is a cardiac specific homeobox gene critical for normal heart development. We previously identified Nkx2.5 as a
target of sumoylation, a posttranslational modification implicated in a variety of cellular activities. Sumoylation enhanced
Nkx2.5 activity via covalent attachment to the lysine residue 51, the primary SUMO acceptor site. However, how
sumoylation regulates the activity of Nkx2.5 in vivo remains unknown. We generated transgenic mice overexpressing
sumoylation deficient mutant K51R (conversion of lysine 51 to arginine) specifically in mouse hearts under the control of
cardiac a-myosin heavy chain (a-MHC) promoter (K51R-Tg). Expression of the Nkx2.5 mutant transgene in the wild type
murine hearts did not result in any overt cardiac phenotype. However, in the presence of Nkx2.5 haploinsufficiency,
cardiomyocyte-specific expression of the Nkx2.5 K51R mutant led to congenital heart diseases (CHDs), accompanied with
decreased cardiomyocyte proliferation. Also, a number of human CHDs-associated Nkx2.5 mutants exhibited aberrant
sumoylation. Our work demonstrates that altered sumoylation status may underlie the development of human CHDs
associated with Nkx2.5 mutants.
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Introduction
Nkx2.5, a cardiac specific homeobox gene, is one of the earliest
markers for cardiac progenitor cells and is central for normal fetal
cardiac structural morphogenesis. Nkx2.5 null mice died from
cardiac malformations [1,2], while mice with Nkx2.5 haploinsuffi-
ciency caused atrial septal defects (ASDs), one of the most
common forms of congenital heart diseases (CHDs) in humans,
although the penetrance was low and was influenced by the mouse
strain [3,4]. The critical role of Nkx2.5 in the conduction system
was revealed by observations in both human patients with
heterozygous Nkx2.5 mutants and in animal models [5,6].
Overexpressing wild type Nkx2.5 or one of its homeodomain
(HD) mutants such as I183P in murine cardiomyocytes under the
control of b-myosin heavy chain promoter resulted in embryonic
lethality and/or heart failure, which was a consequence of dilated
cardiomyopathy and/or a defective conduction system [7].
Transgene expression of the I183P mutant, driven by a-myosin
heavy chain promoter (a-MHC), also led to cardiac dysfunction,
but with later onset [8] and with phenotypic discrepancy [8,9].
Postnatal cardiac specific ablation of Nkx2.5 by tamoxifen-
inducible Cre expression starting at 2 weeks of age led to a
conduction defect and dilated cardiomyopathy [10]. In the clinic,
a multitude of heterozygous Nkx2.5 mutants were shown to be
etiologically implicated in nonsyndromic CHDs [11]. Thus,
Nkx2.5 has an essential role in the formation of cardiac structure
and in the maintenance of cardiac function.
Nkx2.5 is a moderate activator of its target genes. In addition to
its physiological activity achieved via DNA binding through its
HD, it functioned through associations with other transfactors
such as SRF, GATA4 and TBX proteins [12,13,14,15,16,17]. It is
also noteworthy that the transcriptional activity of Nkx2.5 was
modulated in part by posttranslational modification such as
phosphorylation by casein kinase II (CKII) and sumoylation
[18,19]. Sumoylation is a posttranslational modification in which
the SUMO moiety is covalently and reversibly conjugated to the
lysine residue(s) located in the target protein. Sumoylation on
lysine 51 of the Nkx2.5 protein substantially increased its activity,
and mutation of lysine 51 to arginine (K51R) suppressed SUMO
linkage and the activity of Nkx2.5 [18]. However, how the
sumoylation deficient Nkx2.5 mutant behaves in vivo is unknown.
Recent studies pointed to an important role of SUMO
conjugation in cardiac structural morphogenesis and dysfunction
[20,21]. SUMO-1 knockout (KO) mice exhibited cardiac
structural defects, although the phenotypic penetrance may have
been affected by genetic background [22]. Nkx2.5 played a role in
the development of SUMO-1 KO-induced CHDs, because the
compound Nkx2.5+/2/SUMO-1+/2 mice exhibited more severe
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cardiac phenotypes than the mice with single heterozygous
knockout of either Nkx2.5 or SUMO-1 [22]. Given the above
findings and the effect of sumoylation on transcriptional activity of
Nkx2.5 [18], we asked whether CHD-linked Nkx2.5 mutants
exhibited abnormal sumoylation activity and how defective
sumoylation of Nkx2.5 affected cardiogenesis in vivo.We uncovered
that sumoylation was decreased in a number of naturally occurring
Nkx2.5 mutants, including those HD mutants tested, and that
cardiac restricted expression of the sumoylation deficient mutant,
K51R, in the Nkx2.5 haploinsufficient (Nkx2.5+/2) mice led to
CHDs.
Materials and Methods
Ethics Statement
The animals were handled in accordance with institutional
guidelines with appropriate approvals (protocol ID 09018) by
IACUC at Texas A&M Health Science Center.
Generation of transgenic and knockout mice
The human influenza hemagglutinin (HA) tagged K51R mutant
was generated as reported [18] and then was subcloned between
the 5.4 kb mouse a-MHC promoter (provided by Dr. J. Robbins,
University of Cincinnati) and the Simian virus 40 (SV40)
polyadenylation sequence via SalI sites. The orientation of the
inserted transgene was confirmed by DNA sequencing. The
construct was microinjected into the pronucleus of fertilized eggs
from FVB mice, and offspring were screened by polymerase chain
reaction (PCR). One mouse line was identified to transmit
detectable transgene. F0 founder was crossed back to C57BL/6
and scored for positive transmission revealed by PCR using the
following oligos (59 to 39): forward, CGGCACTCTTAGCAAA-
CCTC; reverse, CACCGCCTTCTGCAGCGC. The expression
level of the transgene was evaluated by western blot. K51R-Tg
offspring were then crossed back to C57BL/6 for one to four
generations. Thus, the animals obtained from this cross were
examined under the mixed genetic background of FVB and
C57BL/6. The generation of Nkx2.5 knockout (Nkx2.5+/2) mouse
line was detailed previously [23], in which one Nkx2.5 allele was
disrupted by the homologous recombination of Cre recombinase
cDNA after translation start codon ATG. The cross breeding
between K51R-Tg and Nkx2.5+/2 mouse lines was performed as
needed. Genomic DNA was isolated from tail biopsies performed
on weaned animals (about 3-week old pups) and screened by PCR.
The animals were handled in compliance with institutional
guidelines at Texas A&M Health Science Center at Houston
Campus.
Antibodies
Antibodies against Nkx2.5, HA and GAPDH were purchased
from Santa Cruz Biotechnology, Inc., and anti-flag antibody (M2)
was from Sigma.
Plasmid construction, cell culture, transient transfection
and western blot
The cardiac a-actin promoter driven luciferase reporter
construct (Ca-actin-Luc), the expression vector encoding HA-
tagged wild type Nkx2.5 and flag-tagged SUMO-1 was detailed
previously [15,24]. His6-tagged SUMO-1 cDNA was a gift from
Dr. Hay RT (University of Dundee, UK) and was subcloned into
PCGN vector on XbaI and KpnI sites. All Nkx2.5 point
mutations, R25C (conversion of arginine 25 to cysteine), T177M
(conversion of threonine 177 to methionine), N187K (conversion
of asparagine 187 to lysine), R188G (conversion of arginine 188 to
glycine), Y190C (conversion of tyrosine 190 to cysteine), C265Y
(conversion of cysteine 265 to tyrosine), V309L (conversion of
cysteine 309 to leucine), were generated using Stratagene
mutagenesis kit based on manufacturer’s protocol. Mutations
were confirmed by sequencing. For cell culture, Hela cells were
maintained in Dulbecco’s Modified Eagle’s Medium containing
10% fetal bovine serum. Transfections were performed on Hela
cells cultured on either 6 cm plates for western blot assay or 12
well plates for luciferase activity assay using Lipofectamine 2000
based on the protocol provided by the supplier. For western blot
analysis, 100 mg of protein extracts obtained from mouse hearts
was subjected to NuPage SDS gel (Invitrogen) and transferred to
PVDF membrane, which was labeled with desired antibodies and
revealed by chemiluminescence. Luciferase activity assays were
performed as previously described [18,25]. Briefly, 200 ng of Ca-
actin-Luc was co-transfected with 1 mg of expression vector
encoding wild type Nkx2.5, or one of its mutants R25C,
T177M, N187K, R188G, Y190C, C265Y, V309L, in the absence
or presence of two dosages of flag-SUMO-1 (0.5 mg and 0.75 mg,
respectively). The empty vector was used to balance the total
amount of plasmids used in the reporter assay. Luciferase activity
was assessed after 48 h transfection using MonolightTM 3010
(Pharmingen). Promoter activity was expressed as the ratio of
luciferase activity induced by the presence of specific factor(s) to
the control group with the presence of only empty vector. Data
shown were expressed as mean 6 SEM from at least two
independent assays, with each carried out in duplicate.
In vivo sumoylation assay and Ni2+-NTA chromatography
In vivo sumoylation assay and Ni2+-NTA chromatography were
detailed previously [18,25]. For in vivo sumoylation assay, the
expression vectors for wild type Nkx2.5 or Nkx2.5 mutants were
transfected into Hela cells cultured on 6 cm plates in the presence
or absence of encoding vector for flag-tagged SUMO-1. Whole
cell lysates were purified 48 hours after transfection in the
presence of 25 mM isopeptidase inhibitor N-ethylmaleimide
(NEM), which prevents desumoylation of those SUMO-conjugat-
ed substrates. 40 mg of prepared proteins from each group were
subsequently analyzed in NuPage SDS gel, transferred to PVDF
membrane, which was probed with desired antibodies and
revealed by chemiluminescence. For Ni2+-NTA chromatography,
Hela cell lysates containing expressed Nkx2.5 wild type or one its
mutants in the presence of His6-tagged SUMO-1 were precipitat-
ed by Ni2+-NTA beads, and subsequently subjected to NuPage
SDS gel. The blot was probed with anti-Nkx2.5 antibody and
revealed by chemiluminescence. The relative level of sumoylated
Nkx2.5 wt or its mutants was determined by quantification
followed by normalization of the level of SUMO-conjugated
Nkx2.5 to the level of free Nkx2.5 protein. The level of sumoylated
wt Nkx2.5 was taken as 100%. The data from two independent
assays were analyzed using software ImageJ (National Institutes of
Health).
Histopathology
Mouse neonatal hearts were dissected and fixed in 4%
paraformaldehyde (PFA) at 4uC for overnight. Hearts were
sectioned transversely at 10 mm thickness, which were stained
with Hematoxylin and Eosin (H&E) according to the standard
protocol.
Immunohistochemistry
The mouse hearts at P7 were fixed in 10% formalin prepared in
16phosphate-buffered saline (PBS), dehydrated and embedded in
paraffin for histological sections. For antigen retrieval, 5 mM
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sections were boiled in sodium citrate buffer (10 mM, PH6.0) for
10 minutes, and then blocked in 2% bovine serum albumin
(Vector Laboratories, SP-5050)/PBST (1XPBS/0.05% Tween20),
followed by incubation with the primary antibodies monoclonal
anti-cardiac troponin T (cTnT, 1:200, Lab Vision, MS-295-P) and
rabbit anti-Ki67 (1:200, Abcam, ab15580) in blocking solution at
4uC overnight. Sections were then washed, followed by incubation
with 1:500 Alexa fluorH 594 goat anti-rabbit secondary antibody
(Invitrogen, A31632) and Alexa fluorH 488 donkey anti-mouse
secondary antibody (Invitrogen, A21202) in blocking solution at
RT for 30 minutes. Sections were mounted with VectashieldH
with DAPI (Vector Laboratory) and photographed under a Leica
fluorescent microscope. TUNEL staining was conducted accord-
ing to manufacturer’s protocol (Promega). The number of double
Ki67 positive or TUNEL positive and cTnT positive cells (Ki67+/
cTnT+ or TUNEL/cTnT+) was scored in at least three randomly
selected fields in the left ventricle or atrioventricular septum and
expressed as mean 6 SEM.
Echocardiography
Two dimensional M-mode of Vevo 770 (Visual Sonics,
Toronto, Canada) was used to measure the cardiac function on
mice of interest with various ages as designed. Briefly, mice were
anesthetized by inhalation of 1% isofluorane and fixed to a warm
pad. Chest hair was removed and contacted with the probe to
record cardiac function indices. Evaluations of cardiac function
and heart dimensions were performed by an expert analyst blinded
to the genotype of animals.
Reverse transcription-quantitative PCR (RT-qPCR)
RNAs were extracted from K51R-Tg and age-matched control
mouse hearts using Trizol based on manufacturer’s protocol. 1 or
5 mg total RNAs were used for reverse transcription reaction using
cloned reverse transcriptase (Invitrogen), followed by quantitative
PCR on machine MX3000 (Strategene) using specifically designed
probes for the particular genes of our interest. The sequences (59 to
39) of oligos used in this study were shown below: ANF: forward,
gtgtccaacacagatctgatggat; reverse, gcctagtccactctgggctccaat; BNF:
forward, gaaggtgctgcccagatgattct; reverse, gacggatccgatccggtc-
tatctt; cardiac a-actin [26] : forward, cctctttcattggtatggaatct;
reverse, gtacaatgactgatgagagatgg; cardiac a-MHC [27]: forward,
ggaagagtgagcggcgcatcaagga; reverse, tctgctggagaggttattcctcgt; car-
diac b-MHC: forward, ggccaacaccaacctgtccaagtt; reverse,
tgcaaaggctccaggtctgagggc; MLC-2v [28]: forward, gccaagaagcg-
gatagaagg; reverse, ctgtggttcagggctcagtc; skeletal a-actin [29] :
forward, agacaccatgtgcgacgaaga; reverse, ccgtccccagaatccaacacga;
SERCA forward, gagtcgaccagtcaattcttac; reverse, tcagtattaactc-
cagttgcca; connexin 40: forward, atctcccacattcgttattg; reverse,
aggaagatcccatagaggag; conexin 43 [30]: forward, taccacgccac-
caccggccca; reverse, cattttggctgtcgtcagggaa. GAPDH: forward,
atgttccagtatgactccactcac; reverse, gaagacaccagtagactccacga.
Statistical analysis
The unpaired Student’s t test, Chi-square test was applied to
determine statistical significance between groups when applicable
and shown in each Figure legend.
Results
CHDs-linked Nkx2.5 mutants displayed aberrant SUMO
modification
As an initial step to investigate whether altered sumoylation
status underpinned those Nkx2.5 mutants that were associated
with CHDs, sumoylation assay using Ni2+-NTA chromatography
was performed on Hela cell lysates expressing His6-tagged
SUMO-1 and Nkx2.5 wild type (wt) or one of seven point
mutants created on murine Nkx2.5 protein, R25C, T177M,
N187K, R188G, Y190C, C265Y and V309L (Fig. 1A). These
point mutants corresponded to the following seven missense
human Nkx2.5 mutants respectively that were previously de-
scribed and were involved in human CHDs [5,31]: R25C,
T178M, N188K, R189G, Y191C, C270Y and V315L. As shown
in Fig. 1B, four Nkx2.5 HD mutants tested, T177M, N187K,
R188G, Y190C, showed significant decrease in sumoylation, while
R25C still exhibited robust sumoylation. To better evaluate the
changes in sumoylation activity of Nkx2.5 mutants vs. wt, western
blots, in which loading controls were better monitored, were
carried out on cell lysates purified from transfected Hela cells
expressing Nkx2.5 wt or one of its mutants in the absence or
presence of flag-epitoped SUMO-1, as indicated in Fig. 1C. Also,
the relative level of sumoylated Nkx2.5 wt or mutants after
normalization to the level of corresponding free Nkx2.5 protein
was objectively determined using software ImageJ (Fig. 1D). While
Nkx.2.5 wt and those mutants tested were expressed at
comparable levels, N187K and R188G abolished over 80%
sumoylation compared with Nkx2.5 wt, and T177M, Y190C and
V309L blocked ,50% sumoylation (Fig. 1C&D). Also, C265Y
showed ,30% decrease in SUMO linkage. Among these mutants,
R25C appeared to have a normal sumoylation activity, however,
this ‘‘normal’’ sumoylation status of R25C was achieved with
much lower expression level of SUMO-1 (Fig. 1C. right panel),
indicative of R25C’s high sumoylation affinity.
Since SUMO conjugation promoted the capacity of Nkx2.5 to
activate target gene promoters [18], we next compared the
transcriptional activities of Nkx2.5 wt and those mutants in the
presence of SUMO-1. Luciferase activity assays were performed
on Hela cell lysates expressing Ca-actin-Luc along with Nkx2.5 wt
or one of those above-mentioned mutants in the absence or
presence of increasing dosages of SUMO-1 expression vector as
indicated (Fig. 1E). In line with the observation from sumoylation
assays (Fig. 1C&D), SUMO-1 substantially increased the capacity
of Nkx2.5 wt to activate target gene promoter up to,120 fold, but
this increase was impaired by the HD mutations. C309L mutant
also failed to fully respond to SUMO-1. SUMO-1 enhanced the
capability of C265Y mutant to the equivalent level as Nkx2.5 wt to
stimulate reporter activity. Intriguingly, R25C alone exhibited
higher ability to activate the target promoter by ,34 fold,
compared with ,4 fold activation by wt Nkx2.5, and the addition
of SUMO-1 did not further enhance the transcriptional activity of
R25C. Taken together, these observations indicated that defective
SUMO modification underlied the altered activity of four HD
mutants and one C-terminal mutant (V309L) examined.
Transgene expression of sumoylation deficient Nkx2.5
K51R mutant in the murine heart
Since a number of CHDs-associated Nkx2.5 mutants showed
defective sumoylation, we asked whether sumoylation deficient
Nkx2.5 mutant K51R [18] could be causally linked to CHDs once
expressed in vivo. We generated cardiomyocyte specific expression
of HA-tagged K51R transgene (K51R-Tg) under the control of
cardiac a-MHC promoter (Fig. 2A). One founder of K51R-Tg
mouse transmitted detectable HA-epitoped K51R transgene in
murine hearts (Fig. 2B). The expression level of HA-tagged Nkx2.5
was approximately 1.5,2 folds compared with that of Nkx2.5
protein in the wild type mouse heart, as determined by protein blot
using a specific antibody against Nkx2.5 (Fig. 2C). The offspring
from the cross between K51R-Tg and wild type C57BL/6 mice
were born at the expected Mendelian ratio (,50%), indicating no
Nkx2.5 Sumoylation and Congenital Heart Defects
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embryonic loss. Except that two unusual premature deaths
occurred at postnatal day (P) 2 and 9 (P2 and P9), which carried
atrial septal defect (ASD) (data not shown), all other K51R-Tg
mice appeared normal and fertile.
To gain an insight into cardiac functions in the mice bearing the
K51R mutant, echocardiography was performed on K51R-Tg
and wild type mice at ages of P50 and P300, respectively, using
Vevo 770. Surprisingly, overexpression of the sumoylation
Figure 1. CHDs-associated Nkx2.5 mutants displayed aberrant SUMO modification. A. Schematic illustration of Nkx2.5 wild type and
seven point mutants selected for sumoylation assays. Asterisks * indicated the relative locations of mutations. These seven point mutants generated
on mouse Nkx2.5, R25C, T177M, N178K, R188G, Y190C, C265Y, and V309L, were equivalent to the following corresponding human missense Nkx2.5
mutants, respectively: R25C, Arg-Cys; T178M, Thr-met; N188K, Asn-Lys; R189G, Arg-Gly; Y191C, Tyr-Cys; C270Y, Cys-Tyr; V315L, Cys-Leu. See text for
details. AD, activation domain; HD, homeodomain; RD, repression domain. B. Aberrant sumoylation was observed in Nkx2.5 mutants. Ni2+-NTA
chromatography was performed on Hela cell lysates expressing wt Nkx2.5 or one of those mutants in the presence of His6-tagged SUMO-1. The
representative data from three independent assays were shown. The blot was probed with anti-Nkx2.5 antibody. Arrow indicated His6-SUMO-1-
conjugated Nkx2.5. C. Decreased sumoylation (indicated by *) was observed on all of those four HD mutants and V309L. Western blots were
performed on cell lysates purified from Hela cells transfected with encoding vectors as indicated. Upper blot: anti-Nkx2.5; lower blot: anti-flag. In the
upper panel, upper and lower arrows indicated free and flag-SUMO-1-conjugated Nkx2.5, respectively; in the lower panel, arrows indicated free flag-
tagged SUMO-1. HMW, high molecular weight conjugates. The representative data from two independent assays were shown. D. Summary of the
effects of Nkx2.5 missense mutations on sumoylation activity. Relative level of sumoylated Nkx2.5 wt and its mutants was obtained by normalization
of the level of sumoylated Nkx2.5 to the level of respective free Nkx2.5 protein. The level of sumoylated wt Nkx2.5 was considered as 100%. The data
from two independent assays were analyzed using software ImageJ (National Institutes of Health). E. SUMO-enhanced activity was impaired in those
Nkx2.5 mutants associated with suppressed sumoylation. Luciferase reporter assays were conducted as described in the section of Materials and
Methods. Note that R25C exhibited highest activity in the absence of exogenous SUMO-1, and that the addition of external SUMO-1 did not
significantly increase its activity. Promoter activity was expressed as the ratio of luciferase activity induced by the presence of specific factor(s) to the
control group with the presence of only empty vector. Data shown were expressed as mean 6 SEM from at least two independent assays, with each
carried out in duplicate. Nkx2.5, 1 mg. +, 0.5 mg, ++, 0.75 mg.
doi:10.1371/journal.pone.0020803.g001
Nkx2.5 Sumoylation and Congenital Heart Defects
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20803
resistant Nkx2.5 mutant in mice did not lead to overt defective
cardiac functions (data not shown). In addition, the cardiac index
LV mass/body weight ratio also showed no significant difference
between the two age-matched groups (data not shown). Despite no
discernable cardiac phenotype(s) in the K51R-Tg mice as
evaluated by cardiac function, transcripts of cardiac genes such
as cardiac brain natriuretic peptide (BNP) and myosin light chain
2v (MLC-2v) were elevated in the K51R-Tg hearts at P50
compared with those in the age-matched control hearts (Fig. 3).
However, no significant changes were observed for the transcrip-
tion of conduction function-involving genes such as connexin 40
and connexin 43, which were dysregulated in other mice carrying
overexpressed Nkx2.5 proteins [7,8]. Collectively, overexpression
of K51R mutant in murine hearts caused dysregulation of a subset
of cardiac gene transcriptions, but was insufficient to induce
evident dysfunctional cardiac phenotypes, at least before age of
one year.
Compound K51R-Tg/Nkx2.5+/2 mice exhibited CHDs
In clinic, all Nkx2.5 allele mutations identified in human so far
were heterozygous [32]. We asked whether K51R could induce
similar CHDs in the presence of Nkx2.5 haploinsufficiency. The
compound K51R-Tg/Nkx2.5+/2 mice were obtained after cross-
breeding between K51R-Tg and Nkx2.5+/2 mice. The compound
K51R-Tg/Nkx2.5+/2 mice were born in an expected Mendelian
ratio (26.15%), however, the mortality rate in the first 14 days after
birth was significantly higher than those of three other genotype
groups (Fig. 4 A, K51R-Tg/Nkx2.5+/2 64.71% vs. Wt 5.88%, or
Nkx2.5+/2 7.69% or K51R-Tg 5.56%, respectively, p,0.001),
indicative of severe cardiac dysfunctions. Global heart morphology
showed enlarged hearts from K51R-Tg/Nkx2.5+/2 mice (Fig. 4,
compare E with B, C and D), with both atria glutted with blood,
indicating heart failure. The subsequent histological analysis
revealed the presence of compound ASD/VSD in the K51R-
Tg/Nkx2.5+/2 mouse hearts (compare E9 with B9, C9 and D9) in
10 out of 11 demised K51R-Tg/Nkx2.5+/2 mice examined, and a
single ASD in 1 mouse. Dead pups from other genotype groups
showed either normal structure (Nkx2.5+/2 and K51R-Tg,
respectively) or a single ASD (wt) (Fig. 4F). Thus, expression of
the transgene K51R in the existence of Nkx2.5 haploinsufficiency
caused CHDs, which was likely the primary cause of premature
death observed in the compound K51R-Tg/Nkx2.5+/2 mice.
Decreased cardiomyocyte proliferation in the compound
K51R-Tg/Nkx2.5+/2 mouse hearts
Cardiac structural phenotypes such as ASDs and VSDs can be
associated with decreased proliferation and/or increased apoptosis
of cardiomyocytes [33,34,35]. To explore the molecular basis
underlying the CHDs present in the compound K51R-Tg/
Nkx2.5+/2 mice, cardiomyocyte proliferation in the heart sec-
tions from age-matched wt, K51R-Tg, Nkx2.5+/2 and compound
K51R-Tg/Nkx2.5+/2 mice (n= 3 for each group) at P7 was first
assessed using antibodies against Ki67, a cell proliferating maker
[36], and cardiac troponin-T (cTnT), a cardiomyocyte marker
[37]. As shown in Fig. 5 A–D, the number of proliferating
cardiomyocytes (double Ki67+/cTnT+) in both left ventricle and
atrioventricular septum of the compound K51R-Tg/Nkx2.5+/2
mice was substantially lower than those in other three genotype
animals (number/field: K51R-Tg/Nkx2.5+/2 260.67 vs. wt
10.261.03, Nkx2.5+/2 9.360.95, and K51R-Tg 9.560.85,
p,0.0001, and data not shown). Next, the same tissue sections
mentioned above were stained with TUNEL reagent. The rates of
double TUNEL+/cTnT+ positive cardiomyocytes were similar
between these four genotypes (Fig. 5 F–G, 1–2 cells/field,
p.0.05). Collectively, these findings suggested that defective
cardiomyocyte proliferation but not altered apoptosis underpinned
CHDs present in the compound K51R-Tg/Nkx2.5+/2 mice.
Two out of four surviving compound K51R-Tg/Nkx2.5+/2
mice examined exhibited dilated cardiomyopathy
Although ,65% of the compound K51R-Tg/Nkx2.5+/2 mice
died prematurely, ,35% of them survived to adulthood. We then
asked whether these mice exhibited cardiac dysfunctions. Non-
invasive cardiac function analysis was carried out on surviving
progenies at approximately 4 months age obtained from the cross
between K51R-Tg and Nkx2.5+/2 mice. As shown in Table 1, the
compound K51R-Tg/Nkx2.5+/2 mice exhibited an increase in LV
volume during systole (33.0868.42 ml vs. mice of wt 15.506
9.08 ml, Nkx2.5+/2 13.7865.67 ml, and K51R-Tg 12.3260.83 ml,
respectively), and during diastole (64.95610.93 ml vs. mice of
wt 47.75612.68 ml, Nkx2.5+/2 34.5067.25 ml, and K51R-Tg
48.4761.38 ml, respectively). Also, compound K51R-Tg and
Nkx2.5+/2 mice showed a decrease in cardiac contraction capacity
as indicated by both percent ejection fraction (K51R-Tg/
Nkx2.5+/2 51.6867.53 vs. wt 72.3269.33, Nkx2.5+/2 65.976
9.59, and K51R-Tg 74.4562.3, respectively) and percent fractional
shortening K51R-Tg/Nkx2.5+/2 26.5964.96 vs. wt 41.7567.26,
Nkx2.5+/2 36.8467.13, and K51R-Tg 42.4562.14, respectively).
However, the difference of the above-mentioned indexes between
these groups was not statistically significant due to variations among
individual K51R-Tg/Nkx2.5+/2 mice examined. Further elaborat-
ed interrogation revealed enlarged left ventricular chamber with
impaired cardiac functions in two of four compound K51R-Tg/
Figure 2. Generation of K51R transgenic (K51R-Tg) mice. A.
Structural illustration of construct for generating K51R-Tg mouse line. B.
Transgene HA-tagged K51R was detected in the transgenic heart.
Western blot was carried out on heart lysates extracted from both wild
type and K51R-Tg mice. The blot was probed with anti-HA antibody and
revealed by chemiluminescence. Note that the HA-epitoped K51R was
detected in Tg heart sample (arrow) but not in wild type heart sample.
C. Evaluation of the expression level of transgene HA-tagged K51R.
Western blot was performed as in B and the blot was reacted with anti-
Nkx2.5 antibody first (Upper panel), then stripped and re-probed with
anti-GAPDH antibody as a control (lower panel).
doi:10.1371/journal.pone.0020803.g002
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Figure 3. Dysregulation of cardiac genes in K51R-Tg mice. RT-qPCR revealed altered transcription of some cardiac genes examined such as
BNP and myosin light chain (MLC)-2v in K51R-Tg hearts (n = 6) compared with those of control hearts (n = 4) at P50. RT-qPCR was performed as
described in Materials and Methods. Unpaired student’s t test was used for statistically significant analysis.
doi:10.1371/journal.pone.0020803.g003
Figure 4. Compound K51R-Tg/Nkx2.5+/2 mice exhibited ASD and/or VSD. A. Mortality rate of compound K51R-Tg/Nkx2.5+/2 mice was
significantly higher than those of other genotype mice. The data were collected from 65 animals of 7 litters. The number shown above each bar
indicated the mortality rate of that corresponding group. B–E, Representative gross view of heart morphologies in littermate wt, Nkx2.5+/2, K51R-Tg
and compound K51R-Tg/Nkx2.5+/2 mice at P4 was shown. Note that the atria of the compound K51R-Tg/Nkx2.5+/2 mouse heart were filled with
blood. A9–D9, H&E staining on 10 mm sections of hearts corresponding to A–D was shown. Arrows in D9 indicated ASD and VSD, respectively. Scale
bar, 100 mm. F. Incidence of cardiac defects in the demised mice from four genotype groups. Chi square test was used for statistical analysis. **,
p,0.01, vs. other groups. RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle; ASD, atrial septal defect; VSD, ventricular septal defect.
doi:10.1371/journal.pone.0020803.g004
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Nkx2.5+/2 mice examined (Fig. 6), suggesting dilated cardiomyop-
athy, although the size of the sample needs to be expanded to reach
a statistical significance.
Discussion
Nkx2.5 is a key transcription factor for embryonic cardiogenesis
and its naturally occurring mutations are causally linked to human
cardiac anomalies. Based on our previous findings that Nkx2.5 was
a sumoylation substrate [18], in the present study we investigated
the effects of CHDs-associated Nkx2.5 missense mutations on
Nkx2.5 sumoylation and the impact of accumulated unsumoyla-
table Nkx2.5 mutant K51R on murine heart development and
function.
CHDs-associated Nkx2.5 mutants and sumoylation
activity
The present study revealed that all four Nkx2.5 HD mutants
and one C-terminal domain mutant C309L tested rendered either
substantial or intermediate level of decrease in SUMO conjuga-
tion, respectively, while the intact principle SUMO site was
existent, indicating the involvement of these sites in the regulation
of Nkx2.5 sumoylation. The similar phenomena of modulation of
sumoylation by non-sumoylation site(s) have been observed in
other SUMO targets [38]. The diminished capability of these
Nkx2.5 mutants to be sumoylated was also reflected in the target
promoter activity assays, in which the presence of SUMO-1 failed
to fully potentiate the activity of any of those sumoylation-deficient
mutants compared with that of wild type Nkx2.5. On the other
hand, the R25C mutant showed no significant changes in SUMO
modification. However, it is noteworthy that the mutant R25C
exhibited higher sensitivity to SUMO conjugation compared with
wild type Nkx2.5, because the lower expression of SUMO-1
protein induced its sumoylation to the level equivalent to that of
wild type Nkx2.5 with higher expression of SUMO protein. This
increased sensitivity of R25C to sumoylation probably accounted
for the higher activation of target gene promoter by R25C,
possibly due to active endogenous sumoylation machinery in Hela
cells. And, if this is the case, then the addition of exogenous
SUMO-1 would do little to further increase its activity. However,
this hypothesis needs further investigation. The higher transcrip-
tional activity of R25C mutant observed in the present study was
not observed in a previous report [5]. This discrepancy was likely
attributable to the different systems in which the experiments were
conducted. Increased sumoylation sensitivity was also observed in
other SUMO substrates once a mutation occurred. For instance,
DJ-1, a protein involved in the onset of Parkinson’s disease (PD),
was sumoylated on lysine residue 130 (K130) [39]. The DJ-1
mutant L166P, which was identified in human PD patients,
promoted sumoylation by forming poly- or multi-SUMO-1, and/
or by forming abnormal aggregates [39]. However, the altered
sumoylation of L166P decreased the activity of DJ-1.
How these mutations affected Nkx2.5 sumoylation in the
presence of entire principle SUMO site remains unclear. It
appears that the relative distance from a mutation site to the
SUMO site had no any predictable impact on Nkx2.5 sumoyla-
tion. For instance, four HD mutations and V309L, the former
closer to K51 than C265Y, and the latter farther away from K51
than C265, all showed repressive effects on Nkx2.5 sumoylation.
R25C, on the other hand, which is the most adjacent to K51,
increased the sensitivity of Nkx2.5 to sumoylation. Possibly, these
mutations caused changes of three dimensional structure of
Nkx2.5, which mask the SUMO site and/or make it less accessible
to SUMO pathway components (HD and C309L mutations), or
expose the SUMO site better for sumoylation (R25C mutation).
Alternatively, these sites are required for a direct physical contact
of Nkx2.5 with SUMO pathway factors, and mutations either
disrupt or enhance this contact. The above findings indicate that
all HD mutations of Nkx2.5, which negatively affect its DNA
binding activity, also severely affect its sumoylation. These
observations point to the likelihood that various cardiac pheno-
types associated with different Nkx2.5 mutants are in part
Figure 5. Decreased cardiomyocyte proliferation but not increased apoptosis in the compound K51R-Tg/Nkx2.5+/2 mouse hearts.
Ki67 (A–D) and TUNEL (F–I) staining was performed on 5 mm sections of mouse hearts from four genotype groups at P7 as indicated. cTnT was
indicated for cardiomyocytes, and DAPI for nucleus. Statistical analyses of assays of cardiomyocyte proliferation and apoptosis were shown in E and J,
respectively. The number of double positive (Ki67+/cTnT+ or TUNEL/cTnT+) cells was scored from at least three randomly selected fields in left
ventricle per animal. Arrows in F–I indicated double positive (TUNEL/cTnT+) cardiomyocytes. N = 3 for each group. ***, p,0.001. Scale bar, 100 mm.
doi:10.1371/journal.pone.0020803.g005
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Table 1. Cardiac functional analysis in the progenies obtained from cross-breeding between K51R-Tg and Nkx2.5+/2 mouse lines.
Genotypes
wt Nkx2.5+/2 K51R-Tg K51R-Tg/Nkx2.5+/2
(n = 3) (n=4) (n =3) (n =4)
Diameters; s (mm) 2.0160.47 1.9160.37 1.9760.05 2.8560.35
Diameters; d (mm) 3.3660.36 2.9460.28 3.4360.04 3.8460.28
Volume; s (ml) 15.5069.08 13.7865.67 12.3260.83 33.0868.42
Volume; d (ml) 47.75612.68 34.5067.25 48.4761.38 64.95610.93
stroke volume (ml) 32.2563.95 21.2263.01 36.1462.17 31.8863.84
%EF 72.3269.33 65.9769.59 74.4562.37 51.6867.53
%FS 41.7567.26 36.8467.13 42.4562.14 26.5964.96
cardiac output (ml/min) 12.8762.24 9.3961.39 14.4160.41 13.4261.83
LV mass (mg) 123.17612.72 111.88618.32 113.53611.84 128.80616.49
BW (g) 25.2562.80 25.2562.33 25.7361.95 24.6562.95
LV mass/BW 4.6060.42 4.6060.93 4.4060.16 5.3060.51
Echocardiography was performed on animals of 4 months age as described in Materials and Methods. Note that although there was no statistically significant difference
reached in all parameters shown between compound K51R-Tg/Nkx2.5+/2 group and the other three groups due to small size of the sample examined, there was a trend
of increase in diastolic and systolic volumes, and a trend of decrease in cardiac function (%EF and %FS) in the compound K51R-Tg/Nkx2.5+/2 mice compared with the
other group animals. EF, ejection fraction; FS, fractional shortening.
doi:10.1371/journal.pone.0020803.t001
Figure 6. Two out of four surviving compound K51R-Tg/Nkx2.5+/2mice exhibited dilated cardiac chamber and cardiac dysfunction.
Representative echocardiography images from age-matched four genotype animals were shown. Note the dilated left ventricular chamber in K51R-
Tg/Nkx2.5+/2 mouse. Red broken line: left ventricular internal diameter (LVID, diastolic); green broken line: left ventricular internal diameter (LVID,
systolic). EF, ejection fraction; FS, fractional shortening.
doi:10.1371/journal.pone.0020803.g006
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attributable to the different degrees of altered sumoylation activity
of Nkx2.5 mutants.
Sumoylation-deficient Nkx2.5 K51R mutant and CHDs
Previous studies demonstrated that expressing wild type Nkx2.5
or one HD mutant I183P caused embryonic lethality or cardiac
anomalies [7,8]. In contrast to the above observations, cardiac
specific expression of K51R mutant in the wild type mice was not
sufficient to generate significant cardiac defects. Although K51R
and those HD mutants shared certain properties such as
attenuated transcriptional activity and reduced sumoylation [18],
it is possible that K51R and HD mutants could behave differently
in vivo. For example, K51R and HD mutants may disrupt
physical association with different co-factor(s). Alternatively, it may
also involve variable expression levels of the transgenes. However,
in striking contrast to the lack of overt cardiac malformation in
single K51R-Tg mice, a large portion of Nkx2.5 haploinsufficient
mice with overexpressed K51R mutant in heart developed lethal
congenital heart defects – ASD/VSD. It should be pointed out
that the ASD/VSD observed in the compound K51R-Tg/
Nkx2.5+/2 mice might not be attributable only to the defective
sumoylation of K51R; the certain level of dominant negative
activity of K51R mutant should also be taken into consideration
[18]. However, the current findings support the notion that K51R
mutant could mimic those sumoylation deficient CHDs-associated
Nkx2.5 mutants in vivo to generate cardiac structural defects in
the condition of Nkx2.5 haploinsufficiency.
The exact mechanism(s) by which K51R mutant caused CHDs
in the presence of one wild type Nkx2.5 allele remains unclear.
Apparently, apoptosis was not involved, despite it is a critical
process for cardiac development and function. Although normal
cardiomyocyte proliferation was observed in the hearts of Nkx.2.5
null embryos at embryonic day (E) 10.5 [1], overexpression of wild
type Nkx2.5 did increase cardiomyocyte division [40]. Given the
finding that K51R mutant inhibited the transcriptional activity of
wild type Nkx2.5 partially via competing with Nkx2.5 dimeriza-
tion [18], the observation of substantially suppressed cardiomyo-
cyte proliferation in the compound K51R-Tg/Nkx2.5+/2 mice
indicated a positive role of Nkx2.5 in cardiomyocyte division.
Whether this diminished cardiomyocyte proliferation was solely
responsible for the development of CHDs present in the compound
K51R-Tg/Nkx2.5+/2 mice requires further interrogation.
One of the limitations of the approach used in the present study
is that cardiac a-MHC controlled K51R expression was restricted
to myocardium, therefore the anomalies involving great vessels
such as double outlet right ventricle (DORV) and Tetralogy of
Fallot (TOF) that were seen in human patients associated with
heterozygous Nkx2.5 mutants were not expected/observed in our
model. Thus, it will be interesting to see if K51R knockin in
murine model would lead to the development of great vessel
defects that resemble those observed in human patients.
SUMO and cardiovascular disorders
Involvement of the SUMO pathway in a number of pathogenic
processes such as the development of craniofacial defects,
neurodegenerative disease progression and cancer development
has been considerably investigated [41,42,43], however, evidence
for the role of SUMO in the development of cardiovascular
disorders is newly emerging. SUMO targets a number of
transcription factors, such as serum response factor (SRF) [44],
GATA4 [45,46], and myocardin [25], which are essential for
normal cardiac morphogenesis and function [20]. It is important
to note that the covalent attachment of SUMO to the above-
mentioned factors positively regulated their functions, counter to
the general belief that sumoylation serves as a negative regulator of
the activity of substrates. Recently, two naturally occurring
sumoylation-defective mutants of the nuclear structural protein,
lamin A, , were proposed to be potentially linked to human
familial dilated cardiomyopathy [47]. Similarly, the present study
demonstrated altered sumoylation status in a number of human
Nkx2.5 mutants that are implicated in CHDs. Moreover,
expression of sumoylation deficient Nkx2.5 mutant in the mice
with one wild type Nkx2.5 allele caused CHDs. Given the findings
of CHDs in the SUMO-1 mutant mice [22], and identification of a
unique mutation in the cis-regulatory sequence of the SUMO-1
gene in a patient with both cleft lip/palate and ASD [22], our
studies further indicate a significant influence of the SUMO
pathway in the cardiovascular diseases. With the advances in the
phenotypic analysis of additional animal models with genetic
modifications that specifically target the SUMO conjugation
machinery, we believe that the essentiality of an intact SUMO
conjugation pathway for normal cardiac structural morphogenesis
and function will be clarified.
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